F3 and familial pancreatic carcinoma: Such candidates include KRAS and c-MET, and p53.10 Mutated or activated KRAS2 (found in 95% of pancreatic cancers) has been shown in mouse models to increase thrombosis by increasing the expression of tissue factor.43